CHF Solutions, Inc. Announces 42% Revenue Growth for its Third Quarter and Provides Company Update
- Revenue for third quarter ended
September 30, 2018 increased 42 percent compared to the same period in 2017, and 24 percent sequentially over the second quarter of 2018.
- Announced expansion into the post-surgical cardiovascular market, an adjacent market opportunity with a significant unmet clinical need.
- Continued international expansion and announced entrance into the markets in
Germany andThailand . - Continued path to identify complementary diagnostic technologies. Completed acquisition of AcQtrac™ impedance technology and announced collaboration agreements with
NIMedical andDaxor Corporation to evaluate available, market-cleared diagnostic technologies. - Announced completion of all manufacturing transfer activities from
Baxter . - Ended the quarter with
$8.2 million of cash and equivalents and no debt.
“We have delivered double-digit year over year quarterly growth for six quarters in a row,” said
The Company will host a conference call and webcast at
To access the live webcast, please visit Investor Relations |
About
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statement regarding the benefits from using the Aquadex FlexFlow, trends in our revenue, our expansion plan and our future growth and developments. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our business strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
FINANCIALS
CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited and in thousands, except per share amounts) |
||||||||||||||||
Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
2018 | 2017 | 2018 | 2017 | |||||||||||||
Net sales | $ | 1,363 | $ | 957 | $ | 3,499 | $ | 2,722 | ||||||||
Costs and expenses: | ||||||||||||||||
Cost of goods sold | 915 | 782 | 2,686 | 1,912 | ||||||||||||
Selling, general and administrative | 3,713 | 2,671 | 11,489 | 7,478 | ||||||||||||
Research and development | 985 | 367 | 2,107 | 1,002 | ||||||||||||
Total costs and expenses | 5,613 | 3,820 | 16,282 | 10,392 | ||||||||||||
Loss from operations | (4,250 | ) | (2,863 | ) | (12,783 | ) | (7,670 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Other income, net | 10 | 17 | 10 | 28 | ||||||||||||
Warrant valuation expense | - | - | - | (67 | ) | |||||||||||
Change in fair value of warrant liability | - | 4 | - | 1,470 | ||||||||||||
Total other income | 10 | 21 | 10 | 1,431 | ||||||||||||
Loss before income taxes | (4,240 | ) | (2,842 | ) | (12,773 | ) | (6,239 | ) | ||||||||
Income tax expense, net | (1 | ) | (5 | ) | (3 | ) | (6 | ) | ||||||||
Net loss | $ | (4,241 | ) | $ | (2,847 | ) | $ | (12,776 | ) | $ | (6,245 | ) | ||||
Basic and diluted loss per share | $ | (0.61 | ) | $ | (4.55 | ) | $ | (2.47 | ) | $ | (25.36 | ) | ||||
Weighted average shares outstanding – basic and diluted | 6,987 | 626 | 5,171 | 359 | ||||||||||||
Other comprehensive loss: | ||||||||||||||||
Foreign currency translation adjustments | $ | (1 | ) | $ | (1 | ) | $ | (2 | ) | $ | (7 | ) | ||||
Total comprehensive loss | $ | (4,242 | ) | $ | (2,848 | ) | $ | (12,778 | ) | $ | (6,252 | ) | ||||
CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) |
||||||
September 30, 2018 (unaudited) |
December 31, 2017 |
|||||
ASSETS | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | 8,222 | $ | 15,595 | ||
Accounts receivable | 787 | 545 | ||||
Inventory | 1,948 | 1,588 | ||||
Other current assets | 240 | 136 | ||||
Total current assets | 11,197 | 17,864 | ||||
Property, plant and equipment, net | 573 | 570 | ||||
Other assets | 21 | 21 | ||||
TOTAL ASSETS | $ | 11,791 | $ | 18,455 | ||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
Current liabilities | ||||||
Accounts payable and accrued expenses | $ | 617 | $ | 862 | ||
Accrued compensation | 1,315 | 1,021 | ||||
Other current liabilities | 80 | 208 | ||||
Total current liabilities | 2,012 | 2,091 | ||||
Other liabilities | 126 | 126 | ||||
Total liabilities | 2,138 | 2,217 | ||||
Commitments and contingencies | — |
— | ||||
Stockholders’ equity | ||||||
Series A junior participating preferred stock as of September 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | ||||
Series F convertible preferred stock as of September 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 565 and 3,780 shares, respectively, issued and outstanding 565 and 3,780, respectively | — | — | ||||
Preferred stock as of September 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 39,969,435 and 39,966,220 shares, none outstanding | — | — | ||||
Common stock as of September 30, 2018 and December 31, 2017, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 7,074,407 and 3,798,929, respectively | 1 | — | ||||
Additional paid‑in capital | 203,559 | 197,367 | ||||
Accumulated other comprehensive income: | ||||||
Foreign currency translation adjustment | 1,225 | 1,227 | ||||
Accumulated deficit | (195,132 | ) | (182,356 | ) | ||
Total stockholders’ equity | 9,653 | 16,238 | ||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 11,791 | $ | 18,455 | ||
CHF SOLUTIONS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited, in thousands) |
|||||||||
Nine months ended September 30, |
|||||||||
2018 | 2017 | ||||||||
Operating Activities: | |||||||||
Net loss | $ | (12,776 | ) | $ | (6,245 | ) | |||
Adjustments to reconcile net loss to cash flows used in operating activities: | |||||||||
Depreciation and amortization expense | 174 | 656 | |||||||
Stock-based compensation expense | 1,544 | 391 | |||||||
Change in fair value of warrant liability | - | (1,470 | ) | ||||||
Warrant valuation expense | - | 67 | |||||||
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | (242 | ) | (498 | ) | |||||
Inventory | (361 | ) | (660 | ) | |||||
Other current and long-term assets | (104 | ) | 28 | ||||||
Accounts payable and accrued expenses | (78 | ) | (1,038 | ) | |||||
Net cash used in operations | (11,843 | ) | (8,769 | ) | |||||
Investing Activities: | |||||||||
Purchases of property and equipment | (177 | ) | (206 | ) | |||||
Net cash used in investing activities | (177 | ) | (206 | ) | |||||
Financing Activities: | |||||||||
Net proceeds from public stock offering | 4,649 | 8,002 | |||||||
Net proceeds from exercise of warrants | - | 1,981 | |||||||
Net proceeds from the sale of common stock, preferred stock, and warrants | - | 184 | |||||||
Net cash provided by financing activities | 4,649 | 10,167 | |||||||
Effect of exchange rate changes on cash | (2 | ) | (2 | ) | |||||
Net increase (decrease) in cash and cash equivalents | (7,373 | ) | 1,190 | ||||||
Cash and cash equivalents - beginning of period | 15,595 | 1,323 | |||||||
Cash and cash equivalents - end of period | $ | 8,222 | $ | 2,513 | |||||
Supplement schedule of non-cash activities | |||||||||
Warrants issued as inducement to warrant exercise | $ | - | $ | 509 | |||||
Conversion of temporary equity to permanent equity | $ | - | $ | 485 | |||||
Supplemental cash flow information | |||||||||
Cash paid for income taxes | $ | - | $ | 8 | |||||
CONTACTS:
INVESTORS:
Chief Financial Officer
952-345-4205
ir@chf-solutions.com
-or-
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
917-885-7378
jabraham@jqapartners.com
Source: CHF Solutions, Inc.